肿瘤性B细胞来源的IL-10调节弥漫大B细胞淋巴瘤微环境及免疫治疗反应
研究利用在恶性B细胞中条件性敲除IL-10的免疫功能健全小鼠ABC-DLBCL模型,发现IL-10缺失小鼠未治疗时总生存期显著更差,但对常规抗CD20免疫治疗或调节性T细胞清除的敏感性增加。IL-10缺失淋巴瘤形成高度免疫抑制和T细胞耗竭的微环境并伴血管生成增加,对PD-1免疫检查点阻断难治;抗CD20疗效增强与B细胞钙通道上调相关。IL-10相关转录特征可预测接受R-CHOP治疗的DLBCL患者临床结局。
要点
- 恶性B细胞IL-10自分泌信号促进肿瘤细胞生存,旁分泌作用维持免疫反应性微环境。
- IL-10缺失ABC-DLBCL小鼠未治疗时总生存期显著更差,但对 anti-CD20 治疗或 Treg 清除更敏感。
- IL-10缺失淋巴瘤对PD-1检查点阻断难治,抗CD20疗效增强与B细胞钙通道上调相关。
核心结论
- B细胞来源的IL-10通过自分泌信号促进恶性B细胞生存,并通过旁分泌作用维持影响免疫治疗疗效的免疫反应性微环境。
- IL-10相关转录特征可能正确预测接受R-CHOP治疗的DLBCL患者的临床结局。
研究设计与样本
- 研究构建了在恶性B细胞中条件性敲除IL-10的免疫功能健全小鼠ABC-DLBCL模型。
主要发现
- IL-10缺失小鼠未治疗时总生存期显著更差,但对常规抗CD20免疫治疗或调节性T细胞清除的敏感性增加。
- IL-10缺失淋巴瘤获得高度免疫抑制和T细胞耗竭的微环境,伴血管生成增加,导致更具侵袭性的表型,对PD-1免疫检查点阻断难治。
- IL-10缺失小鼠对抗CD20免疫治疗的反应因B细胞钙通道上调而大幅增强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The contribution of interleukin-10 (IL-10), secreted by tumoral B cells, to the progression and shaping of the microenvironment in diffuse large B-cell lymphoma (DLBCL) with activated B-cell-like (ABC) phenotype is not yet completely understood. To shed light on this issue, we generated an immunocompetent mouse model of ABC-DLBCL with conditional knockout of IL-10 specifically in malignant B cells. Paradoxically, these mice had significantly worse overall survival when left untreated but experienced increased sensitivity to conventional anti-CD20 immunotherapy or regulatory T-cell depletion. We identified various immunomodulatory mechanisms involved in this behavior. In particular, we show that IL-10-deficient lymphomas acquire a highly immunosuppressed and T-cell-exhausted microenvironment with increased angiogenesis that results in a more aggressive phenotype, which is refractory to PD-1 immune checkpoint blockade. However, the response of IL-10-deficient mice to anti-CD20 immunotherapy was greatly enhanced by upregulation of calcium channels in B cells. In general, IL-10 autocrine signaling promotes the survival of malignant B cells, whereas the paracrine action of B-cell-derived IL-10 maintains an immunoreactive microenvironment that influences the efficacy of emerging immunotherapy strategies targeting the lymphoma microenvironment. Furthermore, IL-10-associated transcriptional signatures derived from our studies may correctly predict clinical outcomes of patients with DLBCL treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). Thus, our work provides important functional and mechanistic insights into the role of B-cell-derived IL-10 in the biology of ABC-DLBCL.
引用
- Garcia-Lacarte M, Grijalba SC, Melchor J, et al. IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy. Blood. 2025. PMID: 39899878. doi:10.1182/blood.2024025755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。